These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 18984874)

  • 1. The clinical significance of statistical significance.
    Kane RC
    Oncologist; 2008 Nov; 13(11):1129-33. PubMed ID: 18984874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A review of the limitations of statistical analysis of treatment outcomes used in periodontal research.
    Galgut PN
    J Int Acad Periodontol; 2003 Oct; 5(4):92-7. PubMed ID: 14604057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of adaptive two-stage double-arm clinical trials for dichotomous variables.
    Jiang Z; Xue F; Li C; Wang L; Cai H; Zhang C; Xia J
    Contemp Clin Trials; 2010 May; 31(3):242-50. PubMed ID: 20172053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian sample size determination in non-sequential clinical trials: Statistical aspects and some regulatory considerations.
    Grouin JM; Coste M; Bunouf P; Lecoutre B
    Stat Med; 2007 Nov; 26(27):4914-24. PubMed ID: 17559054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding statistical significance.
    Hayat MJ
    Nurs Res; 2010; 59(3):219-23. PubMed ID: 20445438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of randomized controlled trials.
    Stanley K
    Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574
    [No Abstract]   [Full Text] [Related]  

  • 8. [How to assess the size of a clinical trial?].
    Paesmans M
    Rev Mal Respir; 1994; 11(6):547-57. PubMed ID: 7831504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?
    Carroll KJ
    Pharm Stat; 2006; 5(4):283-93. PubMed ID: 17128427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive randomization for multiarm comparative clinical trials based on joint efficacy/toxicity outcomes.
    Ji Y; Bekele BN
    Biometrics; 2009 Sep; 65(3):876-84. PubMed ID: 19173694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ; Dueck A; Sargent DJ
    Cancer Invest; 2008 Jun; 26(5):439-44. PubMed ID: 18568764
    [No Abstract]   [Full Text] [Related]  

  • 12. Multiplicity adjustment big and small in clinical studies.
    Hsu JC
    Clin Pharmacol Ther; 2010 Aug; 88(2):251-4. PubMed ID: 20592727
    [No Abstract]   [Full Text] [Related]  

  • 13. Statistical inference and the design of clinical trials.
    Berry DA
    Biomedicine; 1980 Feb; 32(1):4-7. PubMed ID: 7370380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple-arm superiority and non-inferiority designs with various endpoints.
    Chang M
    Pharm Stat; 2007; 6(1):43-52. PubMed ID: 17323311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A note on the power of Fisher's least significant difference procedure.
    Meier U
    Pharm Stat; 2006; 5(4):253-63. PubMed ID: 17128424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis.
    Lader EW; Cannon CP; Ohman EM; Newby LK; Sulmasy DP; Barst RJ; Fair JM; Flather M; Freedman JE; Frye RL; Hand MM; Jesse RL; Van de Werf F; Costa F;
    Circulation; 2004 Jun; 109(21):e305-7. PubMed ID: 15173053
    [No Abstract]   [Full Text] [Related]  

  • 17. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 18. Randomized clinical trial design for assessing noninferiority when superiority is expected.
    Freidlin B; Korn EL; George SL; Gray R
    J Clin Oncol; 2007 Nov; 25(31):5019-23. PubMed ID: 17971602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size estimation in phase III cancer clinical trials.
    Curran D; Sylvester RJ; Hoctin Boes G
    Eur J Surg Oncol; 1999 Jun; 25(3):244-50. PubMed ID: 10336801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design issues in head and neck clinical trials: a statistician's perspective.
    Fortpied C; Liberatoscioli C; Bogaerts J
    Anticancer Drugs; 2011 Aug; 22(7):682-7. PubMed ID: 21709617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.